For peptide-based cancer vaccines to make their mark on cancer treatment, future studies will need to ensure a robust combination of in vivo CD4+ and CD8+ responses in a package that strongly activates DCs and subsequently T cells in a prolonged fashion, with minimal exhaustion or immune tolerance. The gene discussed is CD4; the disease is cancer.